DEVA

  • Research type

    Research Study

  • Full title

    Dequalinium versus usual care antibiotics for the treatment of bacterial vaginosis (DEVA): a multicentre, randomised, open label, non-inferiority trial

  • IRAS ID

    269405

  • Contact name

    Janet Wilson

  • Contact email

    janet-d.wilson@nhs.net

  • Sponsor organisation

    Leeds Teaching Hospital NHS Trust

  • Eudract number

    2019-002819-25

  • ISRCTN Number

    ISRCTN91800263

  • Duration of Study in the UK

    1 years, 11 months, 30 days

  • Research summary

    Bacterial vaginosis (BV) causes a vaginal discharge that has an unpleasant smell. It is the most common cause of discharge and up to a third of women will get it at some time in their lives. We do not know why BV occurs but there is a change in the balance of the vaginal bacteria with a reduction in the ‘good’ bacteria that protect against infections and an increase in many other bacteria. Current treatments often do not not cure BV completely, but treating BV is important as the symptoms are unpleasant. Also, it can cause miscarriage, premature birth and it increases the risk of catching HIV and other sexually transmitted infections.

    Oral or vaginal antibiotics are recommended for treating BV. These can cause side-effects such as dizziness, nausea and vaginal soreness. Over 1 in 5 women get BV back within one month of treatment and have to take repeated courses of antibiotics. Concern about bacteria becoming resistant to antibiotics and damage to the body’s good bacteria means that non-antibiotic therapies are being considered for BV.

    There is a new treatment available for BV called dequalinium which works as a vaginal antiseptic. Its potential advantages are that it will not damage the good bacteria throughout the body or cause antibiotic resistance. Two studies have suggested that it could be effective and safe but the number of women included were small so the results were not conclusive. Also, dequalinium is more expensive than some of the usual care antibiotics.

    The aim of this study, called DEVA, is to see if dequalinium is as good at treating BV as current BV antibiotics.

  • REC name

    North West - Liverpool Central Research Ethics Committee

  • REC reference

    20/NW/0113

  • Date of REC Opinion

    22 Apr 2020

  • REC opinion

    Further Information Favourable Opinion